{
  "source": "PA-Notification-Nuplazid.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1195-11\nProgram Prior Authorization/Notification\nMedication Nuplazid® (pimavanserin)\nP&T Approval Date 7/2016, 7/2017, 8/2018, 8/2019, 10/2019, 11/2020, 11/2021, 12/2022,\n1/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nNuplazid (pimavanserin) is an atypical antipsychotic indicated for the treatment of hallucinations and\ndelusions associated with Parkinson’s disease psychosis. Nuplazid is not approved for the treatment\nof patients with dementia who experience psychosis unless their hallucinations and delusions are\nrelated to Parkinson’s disease.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Nuplazid will be approved based on the following criteria:\na. Diagnosis of Parkinson’s disease\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Nuplazid will be approved based on the following criterion:\na. Documentation of positive clinical response to Nuplazid therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Nuplazid [package insert]. San Diego, CA: Acadia Pharmaceuticals Inc.; January 2025.\n© 2025 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification – Nuplazid\nChange Control\n7/2016 New program.\n7/2017 Annual review. Updated references.\n8/2018 Annual review. Updated references.\n12/2018 Administrative change to add statement regarding use of automated\nprocesses.\n8/2019 Annual review. Updated references. Clarif",
    "iew. Updated references.\n8/2018 Annual review. Updated references.\n12/2018 Administrative change to add statement regarding use of automated\nprocesses.\n8/2019 Annual review. Updated references. Clarified that hallucination and\ndelusion symptoms started after Parkinson’s disease diagnosis.\n10/2019 Removed hallucinations requirement to match Diagnosis to Drug\nprogram.\n11/2020 Annual review. Updated references.\n11/2021 Annual review. Updated references.\n12/2022 Annual review. Added state mandate language.\n1/2024 Annual review. Updated references. Updated background information.\n3/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}